Helicon is listed on the Australian Securities Exchange. The Company's business is to identify and exploit niche market opportunities in the biomedical markets of North Asia, specifically China and to participate in the significant growth that has been projected for these markets over the next 25 years. Helicon looks for "Special Situations" for advanced Western biopharmaceutical products that are not available in China or other North Asian Markets or where there are market needs that are not being adequately provided for. Helicon's product partners are likely to be innovative small to medium sized pharmaceutical and healthcare enterprises focused largely on western markets. Helicon seeks exclusive licenses for the designated markets and utilises a low cost operating overhead base in combination with established channel partners for product registration, distribution, marketing, and sales.

	Headquarters	Level 1, The Old Swan Brewery 173 Mounts Bay Road
		Perth WA 6000
		Australia
	Telephone	+61-8-9321-9888
	Principal Sector	Health & Pharm
	Principal Industry	Biotechnology
	Homepage	www.helicongroup.com.au

Stock Exchange Stock Code   ASX:HCG HCG

Helicon Group Limited (ASX:HCG) Secures Milestone Regulatory Approval In China For Skin Regeneration Medical Technology ReCell(R) (JULY 3, 2008)

Helicon Group (ASX:HCG) Announce 3rd Party Equity Research Report by Money Cat Consulting (JUNE 5, 2008)

Helicon Group Limited (ASX:HCG) Present The Company Profile and The China Opportunity (MAY 21, 2008)

Helicon Group Limited (ASX:HCG) Secures Exclusive China Rights For Collatamp G, An Innovative Drug Release Surgical Implant (MAY 12, 2008)

Helicon Group Limited (ASX: HCG) Intensifies Efforts To Extend Product Portfolio With Swiss Based Executive Appointment (JAN 31, 2008)

Helicon Group Limited (ASX:HCG) Appoints Aleksandra Gajda To Stakeholder Relations Manager (JAN 24, 2008)

Helicon Group (ASX:HCG) Shareholder Update - Jewim Pharmaceuticals China (JAN 14, 2008)

Helicon Group (ASX: HCG) Sign With Jewim Pharmaceuticals Inc. In Chinese Oncology Market (DEC 10, 2007)

Helicon Group Limited Releases 2007 Annual Report (NOV 2, 2007)

Chinese Regulatory Agency Formally Accepts Helicon Group's ReCell Marketing Application (OCT 29, 2007)

Helicon's CEO (Peter Abrahamson) Relocates To Shanghai To Drive Implementation Of Helicon's Strategy In China (OCT 24, 2007)